ISHL12 Videos

New findings and new challenges since last ISHL

Stephen Ansell

Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure

Paul J. Bröckelmann

Vision Corner: Discussion

Paul J. Bröckelmann, Graham Collins, Christian Steidl

Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment

Graham Collins

Vision Corner Stimulus Talk: The future of translational science in HL

Christian Steidl

Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

Ryan Lynch

Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

John Timmerman

Patient perspective

Louise Jennings, Jack Richardson

Organisation of HL survivorship care in the UK, ADAPT program

John Radford, Tracy Howe

Organisation of HL survivorship care in the Netherlands and design of INSIGHT costeffectiveness study

Berthe Aleman

Organisation of HL survivorship care in the U.S.

Kevin Oeffinger

Spatial Proteomic Analyses of the Intact Tumor Microenvironment in Hodgkin Lymphoma – One Cell or Region at a Time

Scott Rodig

Microenvironmental Lessons from the NIVAHL Trial

Wolfram Klapper

Introduction to GHSG

Peter Borchmann

In memoriam of Ton Hagenbeek

Marie Jose Kersten

Future perspectives for prognostication and MRD in cHL

Sven Borchmann

EV miRNA in cHL

Michiel Pegtel

MTV and Baseline PET biomarkers

Sally Barrington

Latest developments in software and PET technology

Irene Buvat, Carsten Kobe

Imaging response in the context of immunotherapy

Philippe Armand, Martin Hutchings

Lymphoma Biology and Immunosenescence in Older Patients

Alessandra Tucci

Efficacy and Safety of Targeted Drugs in Older HL Patients

Ingrid Glimelius

Current and Future Trial Landscape in Older Patients

Alexander Fosså

Open Discussion Forum: Adressing Unmet Needs

Indications and current policy for radiotherapy in early and advanced stage HL based on GHSG randomized studies

Christian Baues

Who benefits from adding radiotherapy even if PET-negative based on the RAPID study data

David Cutter

The experience of incorporating RT into CAR-T cell salvage programs- Does it apply to HL patients?

Brandon Imber

Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma

Christine Mauz-Körholz

SEARCH for CAYAHL initiative

Jamie Flerlage

Importance of QoL and PROs in long-term follow-up of HL

Susan Parsons

Development and execution of S1826 trial: North American NCTN pediatric/adult collaboration

Jonathan Friedberg

Lessons from European Network for Pediatric Hodgkin Lymphoma

Dieter Körholz

Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma

Sharon Castellino

Liquid Biopsy in Lymphoma: The Swiss Experience

Cristina Pirosa

Liquid Biopsy in Lymphoma: The Cologne experience

Michel Heger

Integrating Fragmentomics and MRD in Lymphoma

Leo Meriranta

Challenges in bringing Liquid Biopsy to Lymphoma patients – Kick-off talk for round table

Sven Borchmann

Where belongs NLPHL? Biology and pathology

Sylvia Hartmann

Treatment of NLPHL: what evidence is available?

Dennis Eichenauer

The GLOW database: a tool to answer open questions in NLPHL

Michael Binkley

Welcome and Introduction to the topic

Peter Borchmann

Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma

Paul J. Bröckelmann

The challenge of the older patient in lymphoma therapy

Graham Collins

New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies

Pier Luigi Zinzani

In memoriam of Saul Rosenberg

Ranjana Advani

Standard treatment of early-stage HL

John Radford

Individual risk assessment of RT in HL

Richard Hoppe

WS Report: NLPHL

Dennis Eichenauer, Michael Binkley, Sylvia Hartmann

Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

Dennis Eichenauer

Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

Andrea Gallamini

Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

Rebecca Shakir

Status quo of CAR T cell therapy for r/r DLBCL

Peter Borchmann

New perspective for the treatment of r/r CLL

Paula Cramer

CAR T – Lessons Learned

Christoph Scheid

Welcoming Address

Andreas Engert

Award Ceremony

Sven Borchmann, Peter Borchmann, Paul J. Bröckelmann, Dennis Eichenauer

Introduction to the Keynote Lecturer

Volker Diehl

Keynote Lecture

Uğur Şahin

Case presentation: Greyzone Lymphoma

László Imre Pinczés

Case presentation: Anti-PD1 Failure

Graham Collins

Case presentation: COVID19 immunity in lymphoma

Sybille Mellinghoff

Case presentation: Primary progressive HL

Anne Sophie Jacob

Emerging indications for cellular therapy

Peter Borchmann

Clinical experience with Cellular Therapy in cH

Barbara Savoldo

Design and manufacturing of CD30 CARs for cHL

Concetta Quintarelli

Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors

Kim Linton

GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study

Karolin Behringer

WS Report: Living beyond Lymphoma

Flora van Leeuwen, Lena Specht

Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

Suzanne Neppelenbroek

Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

Joshua Entrop

Managing an Older Lymphoma Patient

Raul Cordoba Mascuñano

Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.

Michaela Dinan

Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?

Peter Borchmann

The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma

Bastian von Tresckow

Treatment Strategies in Older HL Patients

Andrew Evens

Strategies to enhance checkpoint inhibition

Paul J. Bröckelmann

Workshop Report: Innovation for Older patients

Alexander Fosså, Paul J. Bröckelmann

AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.

Ninja Övergaard

The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

Jenica Upshaw

Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

Irene Buvat

Welcome and introduction

Anna Sureda

Navigating Complex Treatment Decisions in R/R HL

Theodoros Vasilakopoulos

Challenging Case Study #1

Martin Hutchings

Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL

Anna Sureda

Challenging Case Study #2

Martin Hutchings

Audience Q&A

Why I recommend PET-adapted escalated BEACOPP

Peter Borchmann

Why I recommend PET-guided ABVD

Alexander Fosså

Why I recommend BV-AVD

Ranjana Advani

Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective

Martin Dreyling, Sarah Wells, Jack Richardson

WS Report: Learning through International Collaboration

Peter Borchmann, Alison Moskowitz

FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Wouter Plattel

Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Peter Borchmann

HL in Pregnancy

Daan Dierickx

HIV-positive HL

Otavio Baiocchi

alloSCT in the era of anti-PD1

Anna Sureda

Biological Classification of HL by Liquid Biopsy

Sven Borchmann

Single Cell Transcriptomics of HL

Christian Steidl

WS Report: Bringing Liquid Biopsy to Patients

Sven Borchmann, Davide Rossi

Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

Kristiina Karihtala

High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

Arjan Diepstra

Audience Q&A

Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

Julia Paczkowska

Welcome and introduction

Graham Collins

1ˢᵗ Relapse of HL

Craig H. Moskowitz

Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1

Graham Collins

Novel developments in R/R HL

Graham Collins

Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)

Alex Herrera, Graham Collins, Pier Luigi Zinzani

WS Report: PET beyond Deauville

Sally Barrington, Martin Hutchings, Carsten Kobe

Conference Highlights

Ranjana Advani

Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

Anna Sureda

High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

Alison Moskowitz

Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

Catherine Diefenbach